Onderneming Capstone Therapeutics Corp Other OTC
Aandelen
US14068E1091
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Novel Peptides and Other Molecules
100,0
%
| 67 | 100,0 % | 62 | 100,0 % | -7,84% |
Verkoop per regio
USD in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 67 | 100,0 % | 62 | 100,0 % | -7,84% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Toporek
CEO | Chief Executive Officer | 59 | 14-07-17 |
Edward Schultz
DFI | Director of Finance/CFO | - | - |
Matthew Lipman
BRD | Director/Board Member | 45 | 14-07-17 |
Jock Holliman
BRD | Director/Board Member | 70 | 01-09-87 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jock Holliman
BRD | Director/Board Member | 70 | 01-09-87 |
Michael Toporek
CEO | Chief Executive Officer | 59 | 14-07-17 |
Matthew Lipman
BRD | Director/Board Member | 45 | 14-07-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 157 610 | 157 610 ( 100,00 %) | 0 | 100,00 % |
Bedrijfsgegevens
Capstone Therapeutics Corp.
1275 West Washington Street Suite 104
85281, Tempe
+602-286-5520
http://www.capstonethx.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,65% | 49,18 mld. | |
+0,71% | 42,11 mld. | |
+50,47% | 40,37 mld. | |
-5,26% | 28,85 mld. | |
+13,72% | 26,09 mld. | |
-22,36% | 18,71 mld. | |
+8,13% | 13,26 mld. | |
+32,05% | 12,32 mld. | |
+0,04% | 11,99 mld. |